We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lipomics Technologies Sign Research Collaboration Agreement for Pharmacometabolic Markers
News

Lipomics Technologies Sign Research Collaboration Agreement for Pharmacometabolic Markers

Lipomics Technologies Sign Research Collaboration Agreement for Pharmacometabolic Markers
News

Lipomics Technologies Sign Research Collaboration Agreement for Pharmacometabolic Markers

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lipomics Technologies Sign Research Collaboration Agreement for Pharmacometabolic Markers"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lipomics Technologies, Inc. has entered into a two year collaborative research agreement with Duke University in several key clinical areas to identify pharmacometabolomic markers.

Lipomics will provide Duke analytical services for biomarker discovery and validation (using its proprietary platform and technologies relating to lipid profiles) as well as provide data transfer and interpretation services that will streamline the process of biomarker development allowing researchers at Duke easy access to analysis and data.

In return, Lipomics will receive an option to license diagnostic rights on all such markers developed under this agreement through use of Lipomics proprietary technologies. Initial clinical areas are CNS (schizophrenia and depression) and Cardiovascular (response to statins) disorders.

Results from the first project of the collaboration were presented at the Society of Biological Psychiatry meeting in San Diego on May 18th, 2007. The study aimed to define metabolic signatures for patients treated with anti-psychotic drugs.

“We are very excited about this partnership. It is a great honor to work with Duke University, one of the leading academic institutions in the country, to advance our clinical diagnostic program” said Dr. Meeta Patnaik, chief medical officer, Lipomics.

Financial terms of the collaboration were not disclosed.

Advertisement